EP1545586A4 - Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene - Google Patents

Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene

Info

Publication number
EP1545586A4
EP1545586A4 EP03755796A EP03755796A EP1545586A4 EP 1545586 A4 EP1545586 A4 EP 1545586A4 EP 03755796 A EP03755796 A EP 03755796A EP 03755796 A EP03755796 A EP 03755796A EP 1545586 A4 EP1545586 A4 EP 1545586A4
Authority
EP
European Patent Office
Prior art keywords
long acting
tissue protective
protective activity
maintain tissue
endogenous erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03755796A
Other languages
German (de)
English (en)
Other versions
EP1545586A2 (fr
Inventor
Anthony Cerami
John Smart
Michael Brines
Carla Cerami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warren Kenneth S Institute Inc
Warren Pharmaceuticals Inc
Original Assignee
Warren Kenneth S Institute Inc
Warren Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warren Kenneth S Institute Inc, Warren Pharmaceuticals Inc filed Critical Warren Kenneth S Institute Inc
Publication of EP1545586A2 publication Critical patent/EP1545586A2/fr
Publication of EP1545586A4 publication Critical patent/EP1545586A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
EP03755796A 2002-09-09 2003-09-09 Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene Withdrawn EP1545586A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40902002P 2002-09-09 2002-09-09
US409020P 2002-09-09
PCT/US2003/028073 WO2004022577A2 (fr) 2002-09-09 2003-09-09 Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene

Publications (2)

Publication Number Publication Date
EP1545586A2 EP1545586A2 (fr) 2005-06-29
EP1545586A4 true EP1545586A4 (fr) 2007-09-26

Family

ID=31978712

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03755796A Withdrawn EP1545586A4 (fr) 2002-09-09 2003-09-09 Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene

Country Status (15)

Country Link
EP (1) EP1545586A4 (fr)
JP (1) JP2006511468A (fr)
KR (1) KR20050083682A (fr)
CN (2) CN101371920A (fr)
AU (1) AU2003273297A1 (fr)
BR (1) BR0314152A (fr)
CA (1) CA2497960A1 (fr)
EA (1) EA007812B1 (fr)
IL (1) IL174178A0 (fr)
IS (1) IS7731A (fr)
MX (1) MXPA05002617A (fr)
NO (1) NO20051714L (fr)
PL (1) PL375741A1 (fr)
WO (1) WO2004022577A2 (fr)
ZA (1) ZA200505423B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2006061853A2 (fr) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Nouveaux composes erythropoietiques et leur procede de production
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
SI2594279T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
CN108743916A (zh) 2008-01-22 2018-11-06 阿拉伊姆药品公司 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN101671388B (zh) * 2008-09-09 2013-01-02 曹国栋 血脑屏障穿透性促红细胞生成素及其应用
RU2475273C1 (ru) * 2012-04-02 2013-02-20 Юлия Николаевна Козлова Способ получения полимерного цемента медицинского назначения
CN102746405B (zh) * 2012-07-24 2013-08-21 深圳赛保尔生物药业有限公司 重组人促红素的连续聚乙二醇化反应方法
RU2664588C2 (ru) * 2015-11-05 2018-08-21 Закрытое Акционерное Общество "Биокад" Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе
CN109310741A (zh) 2016-04-29 2019-02-05 阿拉伊姆药品公司 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽
CN112741895A (zh) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Epo类似物在制备治疗脓毒症药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081405A2 (fr) * 2000-04-21 2001-11-01 Amgen Inc. Methodes et compositions destinees a la prevention et au traitement de l'anemie
WO2001087329A1 (fr) * 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Nouvelle composition pharmaceutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081405A2 (fr) * 2000-04-21 2001-11-01 Amgen Inc. Methodes et compositions destinees a la prevention et au traitement de l'anemie
WO2001087329A1 (fr) * 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Nouvelle composition pharmaceutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UREÑA PABLO: "Treatment of anemia in chronic renal failure by a long-activing activator of erythropoiesis", PRESSE MEDICALE, vol. 31, no. 11, 23 March 2002 (2002-03-23), ISSN: 0373-0101, pages 505 - 514, XP002444891 *

Also Published As

Publication number Publication date
CA2497960A1 (fr) 2004-03-18
CN101371920A (zh) 2009-02-25
MXPA05002617A (es) 2005-09-08
WO2004022577A2 (fr) 2004-03-18
CN1729015A (zh) 2006-02-01
BR0314152A (pt) 2005-07-12
PL375741A1 (en) 2005-12-12
IL174178A0 (en) 2006-08-01
WO2004022577A3 (fr) 2004-09-16
NO20051714L (no) 2005-06-06
EA200500473A1 (ru) 2005-10-27
EA007812B1 (ru) 2007-02-27
KR20050083682A (ko) 2005-08-26
AU2003273297A8 (en) 2004-03-29
IS7731A (is) 2005-03-08
EP1545586A2 (fr) 2005-06-29
ZA200505423B (en) 2008-08-27
AU2003273297A1 (en) 2004-03-29
JP2006511468A (ja) 2006-04-06

Similar Documents

Publication Publication Date Title
IL174178A0 (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
HK1099014A1 (en) Malonamide derivatives blocking the activity of gama-secretase
SI1583763T1 (sl) Benzoazolilpiperazinski derivati, ki imajo VR1 antagonistično delovanje
IL159439A0 (en) Iodobenzopyran-4-one derivatives having fungicidal activity
IL157456A0 (en) Aryl and biaryl compounds having mch modulatory activity
EP1555957A4 (fr) Scellants pour la peau et autres tissus
HK1085375A1 (en) Topical skin and/or hair compositions containing an hydrolysed protein
DE69900038T2 (de) Kosmetische oder dermatologische Zusammensetzung
EP1575528A4 (fr) Cytokines de protection tissulaire permettant la protection, la restauration et la stimulation de cellules, tissus et organes sensibles
AU2003298837A8 (en) Prolonged suppression of electrical activity in excitable tissues
EP1534353A4 (fr) Materiaux orthopediques derives de la keratine
AU2003241291A8 (en) Vascularized human skin equivalent
AU2003288971A8 (en) Compositions for darkening the skin and/or hair
DE60029063D1 (de) Automatenlegierung
TW510160U (en) Structure of clippers for gardening use
AU152831S (en) Hair trimmer
AU2003299660A8 (en) Wound and skin care compositions
AU2003220567A8 (en) Compostions for darkening the skin
AU2003288972A8 (en) Compositions for darkening the skin and/or hair
AU2003297282A8 (en) Protection of cardiac myocardium
AU2003293582A1 (en) Stimulation of hair regrowth
EP1559719A4 (fr) Nouveaux derives de macrolides potentialisant une activite antifongique
AU2003239844A8 (en) Bioartificial skin comprising genetically modified fibroblasts
FR2834210B1 (fr) Composition cosmetique pour lutter contre le vieillissement cutane
TW504947U (en) Improved structure of scissors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050407

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20070824

17Q First examination report despatched

Effective date: 20071116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100330